Published in Expert Opin Biol Ther on January 04, 2013
Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications. MAbs (2014) 0.94
Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies. Front Pharmacol (2016) 0.82
Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry. MAbs (2014) 0.79
Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod. Drug Des Devel Ther (2016) 0.75
Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab. Biomed Res Int (2017) 0.75
Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab. Ther Clin Risk Manag (2013) 0.75
Differentiating biosimilarity and comparability in biotherapeutics. Clin Rheumatol (2016) 0.75
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J (2002) 1.70
Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitor. Circ Res (2007) 1.48
Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation (2002) 1.22
The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. Thromb Res (2012) 1.17
Plasminogen activator inhibitor-1. Curr Med Chem (2004) 1.10
Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C. J Biol Chem (2006) 1.04
Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am J Physiol Endocrinol Metab (2005) 1.01
Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials. Invest Ophthalmol Vis Sci (2003) 0.98
The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost (2004) 0.97
Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Thromb Vasc Biol (2007) 0.94
Development of ELISAs measuring the extent of TAFI activation. Arterioscler Thromb Vasc Biol (2005) 0.88
Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases. J Biol Chem (2004) 0.87
Mechanisms of conversion of plasminogen activator inhibitor 1 from a suicide inhibitor to a substrate by monoclonal antibodies. J Biol Chem (2002) 0.86
Biochemical importance of glycosylation of plasminogen activator inhibitor-1. Thromb Haemost (2003) 0.86
Modulation of serpin reaction through stabilization of transient intermediate by ligands bound to alpha-helix F. J Biol Chem (2007) 0.85
A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state. Mol Pharmacol (2008) 0.84
Remarkable stabilization of plasminogen activator inhibitor 1 in a "molecular sandwich" complex. Biochemistry (2013) 0.84
Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1. Thromb Res (2011) 0.84
Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays. Ther Drug Monit (2015) 0.84
Characterization and comparative evaluation of a novel PAI-1 inhibitor. Thromb Haemost (2002) 0.83
Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility. J Mol Biol (2011) 0.83
Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion. Thromb Haemost (2004) 0.83
His374 of wheat endoxylanase inhibitor TAXI-I stabilizes complex formation with glycoside hydrolase family 11 endoxylanases. FEBS J (2005) 0.83
Redirection of the reaction between activated protein C and a serpin to the substrate pathway. Thromb Res (2007) 0.83
Urokinase-type plasminogen activator promotes paracellular transmigration of neutrophils via Mac-1, but independently of urokinase-type plasminogen activator receptor. Circulation (2011) 0.82
Generation of a stable activated thrombin activable fibrinolysis inhibitor variant. J Biol Chem (2006) 0.81
High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease. Thromb Res (2010) 0.81
Factor VII-activating protease promotes the proteolysis and inhibition of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol (2011) 0.80
Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis. Semin Thromb Hemost (2013) 0.80
Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization. Ther Drug Monit (2014) 0.80
Advances in understanding pectin methylesterase inhibitor in kiwi fruit: an immunological approach. Planta (2010) 0.80
Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition. Thromb Haemost (2003) 0.80
The conversion of active to latent plasminogen activator inhibitor-1 is an energetically silent event. Biophys J (2005) 0.79
Immobilization of the distal hinge in the labile serpin plasminogen activator inhibitor 1: identification of a transition state with distinct conformational and functional properties. J Biol Chem (2003) 0.79
Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies. Biochem J (2011) 0.79
Tryptophan properties in fluorescence and functional stability of plasminogen activator inhibitor 1. Biophys J (2003) 0.79
Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits. Am J Respir Cell Mol Biol (2015) 0.79
The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant? Thromb Haemost (2004) 0.79
Importance of N-terminal residues in plasminogen activator inhibitor 1 on its antibody induced latency transition. Thromb Haemost (2002) 0.79
Nebulized fibrinolytic agents improve pulmonary fibrinolysis but not inflammation in rat models of direct and indirect acute lung injury. PLoS One (2013) 0.79
Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol (2003) 0.79
Platelet activation and high tissue factor level predict acute stent thrombosis in pig coronary arteries: prothrombogenic response of drug-eluting or bare stent implantation within the first 24 hours. Thromb Haemost (2006) 0.78
Quantitation of Vervet monkey (Chlorocebus aethiops) plasminogen activator inhibitor-1 in plasma and platelets. Thromb Haemost (2006) 0.78
Function-stabilizing mechanism of plasminogen activator inhibitor type 1 induced upon binding to alpha1-acid glycoprotein. Biochemistry (2005) 0.78
Enhanced expression of plasminogen activator inhibitor-1 by dedifferentiated thyrocytes. Biochem Biophys Res Commun (2002) 0.77
Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences. J Struct Biol (2010) 0.77
Protonation state of a single histidine residue contributes significantly to the kinetics of the reaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator. J Biol Chem (2004) 0.77
Study of recombinant antibody fragments and PAI-1 complexes combining protein-protein docking and results from site-directed mutagenesis. Structure (2007) 0.77
Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model. Blood (2011) 0.76
Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo. Thromb Res (2011) 0.76
Effect of Reteplase and PAI-1 antibodies on postoperative adhesion formation in a laparoscopic mouse model. Surg Endosc (2008) 0.76
Comparative study of inhibitory antibody derivatives towards thrombin activatable fibrinolysis inhibitor. Thromb Haemost (2009) 0.76
Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples. Inflamm Bowel Dis (2016) 0.76
Biopharmaceuticals: reference products and biosimilars to treat inflammatory diseases. Ther Drug Monit (2017) 0.76
Development and evaluation of monoclonal antibodies as probes to assess the differences between two tomato pectin methylesterase isoenzymes. J Immunol Methods (2009) 0.75
Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential. Thromb Haemost (2017) 0.75
Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms. Thromb Haemost (2011) 0.75
Haemostatic biomarkers are associated with long-term recurrent vascular events after ischaemic stroke. Thromb Haemost (2016) 0.75
Glycosylation influences the stability of human plasminogen activator inhibitor-1. Blood Coagul Fibrinolysis (2012) 0.75
Corrigendum: PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nat Med (2015) 0.75
Site-directed targeting of plasminogen activator inhibitor-1 as an example for a novel approach in rational drug design. J Biol Chem (2004) 0.75
Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility. Biochem Biophys Res Commun (2004) 0.75
Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1). Thromb Haemost (2009) 0.75
Elucidation of the paratope of scFv-8H9D4, a PAI-1 neutralizing antibody derivative. Thromb Haemost (2003) 0.75